Clinical Study
Hematopoietic Stem-Cell Transplantation in the Developing World: Experience from a Center in Western India
Table 7
Outcome parameters of our autologous and allogeneic patients till April 2014 after a median follow-up of 39 months.
| Outcome data | Autologous | Allogeneic |
| (1) Median engraftment day (Range) | 15 days (10–35 days) | 14 days (9–34 days) |
| (2) Median posttransplant hospital stay (range) | 18 days (10–80 days) | 20 days (14–70 days) |
| (3) Mortality rate | 30-day mortality: = 0 100-day mortality: = 1 1-year mortality: = 7 3-year mortality: = 12 39-month (median follow-up) mortality: = 12 Current mortality: = 14 | 30-day mortality: = 0 100-day mortality: = 3 1-year mortality: = 6 3-year mortality: = 6 39-month (median follow-up) mortality: = 6 Current mortality: = 6 |
| (4) Current disease status | Complete remission: = 16 Partial remission: = 2 Relapse but alive: = 3 | Complete remission: = 7 Partial remission: = 0 Relapse but alive: = 2 |
| (5) OS at median (39 months) follow-up | 65.7% ( = 23) | 57.1% ( = 8) |
|
|